Charles River Laboratories Schedules First-Quarter 2024 Earnings Release and Conference CallBusiness Wire • 04/12/24
Charles River and Deciphex Launch Patholytix Foresight, a Transformative AI-Powered Decision Support Tool for Toxicologic PathologyBusiness Wire • 04/11/24
Charles River Announces Rare Disease Gene Therapy Collaboration with Axovia TherapeuticsBusiness Wire • 04/09/24
Charles River Laboratories Showcases Technology-Driven Capabilities at AACR 2024Business Wire • 04/01/24
Charles River Announces Extension of Gene Therapy Manufacturing Alliance with NUS Yong Loo Lin School of MedicineBusiness Wire • 03/21/24
Charles River and Navega Therapeutics Announce Comprehensive Gene Therapy Manufacturing CollaborationBusiness Wire • 03/14/24
Epic Bio to Present at the Upcoming Charles River Cell and Gene Therapy SummitGlobeNewsWire • 03/13/24
Wheeler Bio Seals Agreement with Charles River to Offer Portable CMC® to Discovery Clients to Accelerate Their Journey to First-in-Human UsePRNewsWire • 02/29/24
Charles River and Wheeler Bio Complete Agreement to Accelerate the Journey from Discovery and CMC Development to ManufacturingBusiness Wire • 02/21/24
Charles River Collaborates with Pluristyx, Expanding its Portfolio of Human Pluripotent Stem CellsBusiness Wire • 02/20/24
The Next Johnson & Johnson? 3 Healthcare Stocks That Investors Shouldn't Ignore.InvestorPlace • 02/15/24
Charles River Laboratories International, Inc. (CRL) Q4 2023 Earnings Call TranscriptSeeking Alpha • 02/14/24
Charles River (CRL) Reports Q4 Earnings: What Key Metrics Have to SayZacks Investment Research • 02/14/24
Charles River Laboratories Announces Fourth Quarter and Full-Year 2023 Results and Provides 2024 GuidanceBusiness Wire • 02/14/24